Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 35Carcinoma, Hepatocellular 28Stomach Neoplasms 12Neoplasm Metastasis 12Nasopharyngeal Carcinoma 11Neoplasms 10Esophageal Neoplasms 10Melanoma 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 8Recurrence 7Lung Neoplasms 7Breast Neoplasms 7Biliary Tract Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Hyperthermia 3

Interventions

Sunitinib 4Cyclophosphamide 4Capecitabine 4Bevacizumab 4pazopanib 3Topotecan 3Paclitaxel 3Docetaxel 3Carboplatin 3temsirolimus 2liposomal doxorubicin 2fludarabine 2Sorafenib 2Panobinostat 2NVP-BKM120 2Lapatinib 2Irinotecan 2Immune Checkpoint Inhibitors 2Gemcitabine 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Bortezomib 2vadimezan 1spartalizumab 1somatostatin receptor 2 1selinexor 1selicrelumab 1perifosine 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Solid Tumors × Immune Checkpoint Inhibitors × Clear all
NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Tongji Hospital

Phase 2 Not yet recruiting
60 enrolled
Other solid neoplasm

Solid Tumors

NCT05522582 2024-10-26

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Yancheng First People's Hospital

Phase 2 Active not recruiting
50 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡